Comparison of Midazolam Plasma Concentrations in ARDS Patients with and Without ECMO Support—Prospective Observational Pilot Study
Life · 10.07.2026 · 16 (7) · 1144
DOI: 10.3390/life16071144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 10.07.2026. Verfasst von Marek Grochla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Therapy in Zabrze, Medical University of Silesia in Katowice, Ul. Marii Skłodowskiej-Curie 9, 41-800 Zabrz…. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Polish National Science Centre.
Abstract (Originalsprache)
Introduction
Patients undergoing ECMO therapy have a much higher need for drug therapy due to the increased volume of distribution and deeper levels of sedation. The influence of ECMO support on the achieved midazolam concentrations is unknown. Materials and Methods: This prospective, single-center study was conducted between October 2022 and December 2024. All mechanically ventilated patients with an FiO2 over 0.6 or requiring VV ECMO for respiratory support were included. Patients younger than 18 years, patients without midazolam infusion, and patients with a do-not-resuscitate protocol were excluded. Patients were divided into a group requiring ECMO therapy (group A, n = 14, 88 measurements) and a group receiving conventional respiratory support (group B, n = 11, 44 measurements). Mean daily doses of midazolam and achieved midazolam concentrations were compared. Chi-squared tests, Mann–Whitney U tests, Pearson’s r correlation, and Spearman’s rank correlation were used to assess statistical significance between groups, where appropriate.
Results
In terms of demographic data, patients in group A were comparable to group B, except that patients in group A had a lower BMI (25.7 ± 5.1 kg/m2 vs. 34.0 ± 10.1 kg/m2, p = 0.014). Midazolam requirements in the ECMO group were higher (3.6 ± 1.6 mg/kg vs. 1.8 ± 1.3 mg/kg, p < 0.001). Despite this, midazolam plasma concentrations in both groups were comparable, and only midazolam metabolites were found to be higher in group A (60 ± 72 ug/L vs. 22 ± 19 ug/L; p < 0.001).
Conclusions
The use of probably higher doses of midazolam does not translate into higher plasma midazolam concentrations in ECMO patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology and Intensive Therapy in Zabrze, Medical University of Silesia in Katowice, Ul. Marii Skłodowskiej-Curie 9, 41-800 Zabrze, Poland.
- Department of Internal Medicine and Clinical Pharmacology in Katowice, Medical University of Silesia in Katowice, Ul. Medyków 14, 40-752 Katowice, Poland.
ORCID-Profile: Marek Grochla, Marcin Basiak, Bogusław Okopień
Förderung
- National Science Centre
- Polish National Science Centre
Zitieren
APA
Grochla, M., Basiak, M., Okopień, B., Trejnowska, E., & Knapik, P. (2026). Comparison of Midazolam Plasma Concentrations in ARDS Patients with and Without ECMO Support—Prospective Observational Pilot Study. Life, 16(7), 1144. https://doi.org/10.3390/life16071144
Vancouver
Grochla M, Basiak M, Okopień B, Trejnowska E, Knapik P. Comparison of Midazolam Plasma Concentrations in ARDS Patients with and Without ECMO Support—Prospective Observational Pilot Study. Life. 2026;16(7):1144. doi:10.3390/life16071144
BibTeX
@article{Grochla2026,
author = {Grochla, Marek and Basiak, Marcin and Okopień, Bogusław and Trejnowska, Ewa and Knapik, Piotr},
title = {Comparison of Midazolam Plasma Concentrations in ARDS Patients with and Without ECMO Support—Prospective Observational Pilot Study},
journal = {Life},
year = {2026},
volume = {16},
number = {7},
pages = {1144},
doi = {10.3390/life16071144}
}
EUVIMED